Floatz logo

Cintredekin Besudotox

Oligoastrocytoma

INSYS Therapeutics Incprotein_peptidePhase 1/2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Oligoastrocytoma cohort.

Asset / SponsorPhaseRating
Adriamycin
Washington University School of Medicine
Phase 2CCC
Chlorotoxin
TransMolecular
Phase 2CCC
Etoposide
Washington University School of Medicine
Phase 2CCC
GBM6-AD
Jennie Taylor
Phase 1CC
Irinotecan
Washington University School of Medicine
Phase 1CC

View all 12 →

Same molecule, other indications

Cintredekin Besudotox is also rated in:

glioblastomaDormant
BB
Indicative · Phase 3
68 / 100
View asset →
anaplastic astrocytomaDormant
BB
Indicative · Phase 1/2
65 / 100
View asset →
malignant gliomaDormant
B
Indicative · Phase 1/2
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →